ReviewWorld journal of gastroenterology2006
Colon cancer and the immune system: the role of tumor invading T cells.
Review in World journal of gastroenterology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Prognostic role of the lymphocyte-to-monocyte ratio in colorectal cancer: An up-to-date meta-analysis.Medicine · 2017Pooled it
- Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis.Scientific reports · 2015Pooled it
- In Silico Analysis of the Dual Role of Tumor Microenvironment on Colon Cancer Subtypes.Cancer informatics · 2026Article
- Lypd6b depletion promotes CD8Nature communications · 2025Article
- Review
- Spotting the clues: cluster of differentiation-a perspective of immune response intertwined with dysautonomia in colon cancer - a prospective cohort study.Journal of medicine and life · 2025Article
- Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy.Cancers · 2024Review
- Prognosis and immunotherapy response prediction based on M2 macrophage-related genes in colon cancer.Journal of cancer research and clinical oncology · 2024Article
- Prognostic cellular senescence-related lncRNAs patterns to predict clinical outcome and immune response in colon cancer.Frontiers in immunology · 2024Article
- Isolation and high-dimensional flow cytometric analysis of tumor-infiltrating leukocytes in a mouse model of colorectal cancer.Frontiers in immunology · 2024Article
- Current perspective on biological properties of plasmacytoid dendritic cells and dysfunction in gut.Immunity, inflammation and disease · 2023Review
- Interleukins (Cytokines) as Biomarkers in Colorectal Cancer: Progression, Detection, and Monitoring.Journal of clinical medicine · 2023Review
- Construction of a Pearson- and MIC-Based Co-expression Network to Identify Potential Cancer Genes.Interdisciplinary sciences, computational life sciences · 2022Article
- Pathological Characteristics, Prognostic Determinants and the Outcome of Patients Diagnosed with Colorectal Adenocarcinoma at the University Teaching Hospital of Kigali.Canadian journal of gastroenterology & hepatology · 2022Article
- Identification of macrophage related gene in colorectal cancer patients and their functional roles.BMC medical genomics · 2021Article
- An Immune-Clinical Prognostic Index (ICPI) for Patients WithFrontiers in oncology · 2021Article
- Therapeutic effects of dihydroartemisinin in multiple stages of colitis-associated colorectal cancer.Theranostics · 2021Article
- Immunobiology of cholangiocarcinoma.JHEP reports : innovation in hepatology · 2019Review
- BioTarget: A Computational Framework Identifying Cancer Type Specific Transcriptional Targets of Immune Response Pathways.Scientific reports · 2019Article
- Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier).Cancer management and research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colon cancer is still one of the leading causes of cancer death worldwide. Although the host immune system has been shown to react against tumor cells, mainly through tumor infiltrating lymphocytes and NK cells, tumor cells may utilize different ways to escape anti-tumor immune response. Tumor infiltration of CD8+ and CD4+ (T-bet+) effector T cells has been attributed to a beneficial outcome, and the enhancement of T cell activation through T cell receptor stimulation and co-stimulatory signals provides promising strategies for immunotherapy of colon cancer. Growing evidence supports a role for the Fas/FasL system in tumor immunology, although the mechanisms and consequences of FasL activation in colon cancer are not completely understood. In animal models, depletion of regulatory T cells (CD4+ CD25+ T cells) can enhance the anti-tumor immune response under certain conditions. Taken together, recent insights in the immune reaction against colon carcinoma have provided new approaches to immunotherapy, although much remains to be learned about the exact mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.